Next Article in Journal
Cellulose Biosynthesis Inhibitors: Comparative Effect on Bean Cell Cultures
Previous Article in Journal
Synthesis and Antimicrobial Studies of Some Novel Bis-[1,3,4]thiadiazole and Bis-thiazole Pendant to Thieno[2,3-b]thiophene Moiety
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2012, 13(3), 3671-3684;

Synthesis and Biological Activities of a 3'-Azido Analogue of Doxorubicin Against Drug-Resistant Cancer Cells

School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China
Department of Chemistry and Biochemistry, The Ohio State University, Ohio 43210, USA
Jinan Central Hospital Affiliated to Shandong University, Jinan 250011, China
College of Chemistry and Environmental Sciences, Henan Normal University, Xinxiang 453002, China
College of Pharmacy, The University of Michigan, Michigan 48109, USA
College of Pharmacy, Nan Kai University, Tianjin 300071, China
Authors to whom correspondence should be addressed.
Received: 13 February 2012 / Revised: 7 March 2012 / Accepted: 13 March 2012 / Published: 19 March 2012
Full-Text   |   PDF [467 KB, uploaded 19 June 2014]


Doxorubicin (DOX), an anthracycline antibiotic, is one of the most active anticancer chemotherapeutic agents. The clinical use of DOX, however, is limited by the dose-dependant P-glycoprotein (P-gp)-mediated resistance. Herein, a 3′-azido analogue of DOX (ADOX) was prepared from daunorubicin (DNR). ADOX exhibited potent antitumor activities in drug-sensitive (MCF-7 and K562) and drug-resistant cell lines (MCF-7/DNR, K562/DOX), respectively. The drug resistance index (DRI) values of ADOX were much lower than that of DOX. The cytotoxicity experiments of ADOX or DOX against K562/DOX, with or without P-gp inhibitor, indicated that ADOX circumvents resistance by abolishing the P-gp recognition. This conclusion was further supported by drug influx/efflux flow cytometry experiments, as well as by molecular docking of ADOX to P-gp. In vivo animal tests, ADOX exhibited higher activity and less toxicity than DOX. The current data warranted ADOX for additional pre-clinical evaluations for new drug development. View Full-Text
Keywords: anthracycline; Azido; multidrug resistance; ADOX; P-gp anthracycline; Azido; multidrug resistance; ADOX; P-gp
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Yu, S.; Zhang, G.; Zhang, W.; Luo, H.; Qiu, L.; Liu, Q.; Sun, D.; Wang, P.-G.; Wang, F. Synthesis and Biological Activities of a 3'-Azido Analogue of Doxorubicin Against Drug-Resistant Cancer Cells. Int. J. Mol. Sci. 2012, 13, 3671-3684.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top